Becampanel

Becampanel (INN; development code AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC₅₀ = 11 nM).^[1][2][3][4] It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.^[1][2][3][5]

Becampanel

Clinical data
ATC code	None
Identifiers
IUPAC name ({[(2,3-Dihydroxy-7-nitro-5-quinoxalinyl)methyl]amino}methyl)phosphonic acid
CAS Number	188696-80-2
PubChem CID	5491960
ChemSpider	4590791
UNII	X3D0O800AJ
CompTox Dashboard (EPA)	DTXSID50172241
Chemical and physical data
Formula	C10H11N4O7P
Molar mass	330.193 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1c(cc2c(c1CNCP(=O)(O)O)[nH]c(=O)c(=O)[nH]2)[N+](=O)[O-]
InChI InChI=1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21) Key:ABFMMCZFKUIJGQ-UHFFFAOYSA-N